A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD

Yu Ri Im, Harriet Hunter, Dana Gracia Hahn, Amedine Duret, Qinrong Cheah, Jiawen Dong, Madison Fairey, Clarissa Hjalmarsson, Alice Li, Hong Kai Lim, Lorcán McKeown, Claudia‐Gabriela Mitrofan, Raunak Rao, Mrudula Utukuri, Ian A. Rowe, Jake P. Mann – 10 May 2021

Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry

Yun Ma, Haibin Su, Muhammed Yuksel, Maria Serena Longhi, Mark J. McPhail, Pengyun Wang, Sanjay Bansal, Guan‐Wee Wong, Jonathon Graham, Li Yang, Richard Thompson, Derek G. Doherty, Nedim Hadzic, Yoh Zen, Alberto Quaglia, Michael A. Heneghan, Marianne Samyn, Diego Vergani, Giorgina Mieli‐Vergani – 9 May 2021

Impact of COVID‐19 in Liver Disease Progression

Miguel Angel Martinez, Sandra Franco – 8 May 2021 – Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is a novel coronavirus that causes coronavirus disease 19 (COVID‐19), which has infected millions of people worldwide in only a few months. A minority, but significant number, of infected individuals require hospitalization and intensive care. From the start of this new virus pandemic, it was apparent that obese and/or diabetic individuals had a bad prognosis for COVID‐19 progression, strongly suggesting an association between liver disease and severe COVID‐19.

Alcohol‐Associated Liver Disease Before and After COVID‐19—An Overview and Call for Ongoing Investigation

Andrew M. Moon, Brenda Curtis, Pranoti Mandrekar, Ashwani K. Singal, Elizabeth C. Verna, Oren K. Fix – 8 May 2021 – The Coronavirus Disease 2019 (COVID‐19) pandemic has exacted a heavy toll on patients with alcohol‐associated liver disease (ALD) and alcohol use disorder (AUD). The collective burden of ALD and AUD was large and growing, even before the COVID‐19 pandemic. There is accumulating evidence that this pandemic has had a large direct effect on these patients and is likely to produce indirect effects through delays in care, psychological strain, and increased alcohol use.

Statin Therapy and the Incidence of Thromboembolism and Vascular Events Following Liver Transplantation

Peter E. Frasco, Bashar Aqel, Jeremy M. Alvord, Karl A. Poterack, Isabel Bauer, Amit K. Mathur – 7 May 2021 – Statin therapy may reduce the risk of venous thromboembolism (VTE), which may impact solid organ transplant outcomes. We evaluated the incidence of VTE and other complications after liver transplantation stratified by hyperlipidemia status and statin use using a retrospective cohort study approach. We reviewed all primary orthotopic liver transplantation (OLT) records from January 2014 to December 2019 from our center. Intraoperative deaths were excluded.

The Emerging Role of Viability Testing During Liver Machine Perfusion

Isabel M. A. Brüggenwirth, Otto B. Leeuwen, Robert J. Porte, Paulo N. Martins – 7 May 2021 – The transplant community continues to be challenged by the disparity between the need for liver transplantation and the shortage of suitable donor organs. At the same time, the number of unused donor livers continues to increase, most likely attributed to the worsening quality of these organs. To date, there is no reliable marker of liver graft viability that can predict good posttransplant outcomes.

Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension

Arun Jose, Shimul A. Shah, Nadeem Anwar, Courtney R. Jones, Kenneth E. Sherman, Jean M. Elwing – 7 May 2021 – Portopulmonary hypertension (POPH) is a pulmonary vascular disease associated with significant morbidity and mortality in those with liver disease, conferring a higher mortality in patients awaiting liver transplantation (LT).

Subscribe to